Bio Plus Co., Ltd

A099430

KR7099430001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
4,365 ^KRW	-2.35%		-9.63%	-36.46%

24/01	Elevance Health Offers Stronger-Than-Expected 2024 Earnings Outlook After Fourth-Quarter Beat	MT
24/01	Elevance Health Issues Upbeat 2024 Adjusted. Earnings Outlook After 4Q Revenue Gains	DJ

Novelgen announced that it has received KRW 2.99985 billion in funding from BioPlus Co., Ltd.

November 01, 2021

On November 1, 2021, Novelgen closed the transaction.

Latest news about Bio Plus Co., Ltd

Elevance Health Offers Stronger-Than-Expected 2024 Earnings Outlook After Fourth-Quarter Beat	24/01	MT
Elevance Health Issues Upbeat 2024 Adjusted. Earnings Outlook After 4Q Revenue Gains	24/01	DJ
Tranche Update on BioPlus Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023.	09/11	CI
Tranche Update on BioPlus Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023.	09/11	CI
BioPlus Co., Ltd.'s Equity Buyback announced on May 9, 2023, has expired with 743,436 shares, representing 1.28% for ¥4,990.07 million.	08/11	CI
Elevance Health Lifts Full-Year Earnings Outlook as Third-Quarter Results Rise	18/23/18	MT
Elevance Health 3Q Revenue Rises on Higher Premiums	18/23/18	DJ
BioPlus Acquisition, Avertix Medical Terminate Business Combination Deal	04/23/04	MT
Tranche Update on BioPlus Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023.	09/23/09	CI
BioPlus Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	09/23/09	CI
BioPlus Co., Ltd. authorizes a Buyback Plan.	09/23/09	CI
BioPlus Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Elevance Health to Acquire Specialty Pharmacy BioPlus for Undisclosed Sum	09/22/09	MT
BioPlus to Raise $14.2 Million from Share Sale; Shares Jump 4%	06/22/06	MT
BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in funding	06/22/06	CI
Tranche Update on BioPlus Co., Ltd.'s Equity Buyback Plan announced on December 7, 2021.	08/22/08	CI
BioPlus Co., Ltd.'s Equity Buyback announced on December 7, 2021, has expired with 199,320 shares, representing 1.43% for KRW 4,987.71 million.	07/22/07	CI
BioPlus Co., Ltd.'s Equity Buyback announced on October 13, 2021, has expired.	13/22/13	CI
BioPlus Co., Ltd.(KOSDAQ:A099430) added to S&P Global BMI Index	21/22/21	CI
BioPlus Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	07/21/07	CI
BioPlus Co., Ltd. authorizes a Buyback Plan.	07/21/07	CI
Novelgen announced that it has received KRW 2.99985 billion in funding from BioPlus Co., Ltd.	01/21/01	CI
Novelgen announced that it expects to receive KRW 2.99985 billion in funding from BioPlus Co., Ltd.	29/21/29	CI
BioPlus Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	13/21/13	CI
BioPlus Co., Ltd. authorizes a Buyback Plan.	13/21/13	CI

BioPlus Co Ltd is a Korea-based company principally engaged in the medical device business. The Company is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIO PLUS CO., LTD	-36.46%	181M
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
BIOGEN INC.	-13.07%	32.75B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B

Biopharmaceuticals

Bio Plus Co., Ltd

Equities

A099430

KR7099430001

Pharmaceuticals

Novelgen announced that it has received KRW 2.99985 billion in funding from BioPlus Co., Ltd.

Latest news about Bio Plus Co., Ltd

Chart Bio Plus Co., Ltd

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals